It is approved for absence seizures. Ethosuximide is considered the first choice drug for treating absence seizures in part because it lacks the idiosyncratic hepatotoxicity of the alternative anti-absence drug, valproic acid.
Dosage
Therapeutic drug concentrations are individualized according to response and tolerance. Common serum therapeutic range: 40-100µg/mL. Potentially toxic serum concentration: >100µg/mL.